Effectiveness and safety analysis of switching to tenofovir alafenamide after entecavir or tenofovir treatment

被引：0
|
作者：
Liu, Xue [1 ]
Zhao, Zhihao [1 ]
Kong, Xianggen [2 ]
Cui, Shiyu [2 ]
Jiang, Xuemei [2 ]
机构：
[1] Shandong Univ, Jinan, Peoples R China
[2] Shandong Publ Hlth Clin Ctr, Jinan, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
WED-415
引用
收藏
页码：S804 / S805
页数：2
相关论文
共 50 条
  • [21] Switching tenofovir disoproxil fumarate to tenofovir alafenamide not only bone and kidney
    Berger, F.
    Milinkovic, A.
    Arenas-Pinto, A.
    Mauss, S.
    ANTIVIRAL THERAPY, 2018, 23 : A48 - A48
  • [22] Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir
    Nguyen, Mindie H.
    Atsukawa, Masanori
    Ishikawa, Toru
    Yasuda, Satoshi
    Yokohama, Keisuke
    Trinh, Huy N.
    Arai, Taeang
    Fukunishi, Shinya
    Ogawa, Eiichi
    Hsu, Yao-Chun
    Maeda, Mayumi
    Dang, Hansen
    Tseng, Cheng-Hao
    Takahashi, Hirokazu
    Jun, Dae Won
    Watanabe, Tsunamasa
    Chuma, Makoto
    Nozaki, Akito
    Kawada, Norifumi
    Cheung, Ramsey
    Enomoto, Masaru
    Takaguchi, Koichi
    Toyoda, Hidenori
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (06): : 1264 - 1273
  • [23] Cost-effectiveness of tenofovir alafenamide and entecavir in chronic hepatitis B in Saudi Arabia
    Al-Jedai, Ahmed
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2024, 30 (01): : 1 - 3
  • [24] Switching tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed adults
    Orkin, C.
    Clarke, A.
    Gallant, J.
    Daar, E.
    Raffi, F.
    Antonucci, S.
    Mingjin, Y.
    Chang, A.
    Rhee, M.
    HIV MEDICINE, 2016, 17 : 18 - 18
  • [25] Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir
    Vigano, Mauro
    Loglio, Alessandro
    Labanca, Sara
    Zaltron, Serena
    Castelli, Francesco
    Andreone, Pietro
    Messina, Vincenzo
    Ganga, Roberto
    Coppola, Nicola
    Marrone, Aldo
    Russello, Maurizio
    Marzano, Alfredo
    Tucci, Alessandra
    Taliani, Gloria
    Fasano, Massimo
    Fagiuoli, Stefano
    Villa, Erica
    Bronte, Fabrizio
    Santantonio, Teresa
    Brancaccio, Giuseppina
    Occhipinti, Vincenzo
    Facchetti, Floriana
    Grossi, Glenda
    Rumi, Mariagrazia
    Lampertico, Pietro
    LIVER INTERNATIONAL, 2019, 39 (03) : 484 - 493
  • [26] Safety of tenofovir alafenamide in renal impairment
    Pozniak, A.
    Arribas, J.
    Gupta, S.
    Post, F.
    Avihingsanon, A.
    Crofoot, G.
    Lichtenstein, K.
    Ramgopa, M.
    Chetchotisakd, P.
    Benn, P.
    Fordyce, M. W.
    HIV MEDICINE, 2015, 16 : 33 - 33
  • [27] RENAL AND BONE SAFETY OF TENOFOVIR ALAFENAMIDE VS TENOFOVIR DISOPROXIL FUMARATE
    Post, Frank
    Sax, Paul
    Saag, Michael
    Yin, Michael
    Oka, Shinichi
    Koenig, Ellen
    Trottier, Benoit
    Andrade, Jaime
    Cao, Huyen
    Fordyce, Marshall
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A48 - +
  • [28] Tenofovir alafenamide versus tenofovir disoproxil fumarate is there a true difference in safety?
    Pepperrell, T.
    Hughes, S.
    Gotham, D.
    Pozniak, A.
    Boffito, M.
    Pilkington, V.
    Hill, A.
    HIV MEDICINE, 2019, 20 : 92 - 92
  • [29] TENOFOVIR AND ENTECAVIR IN THE TREATMENT OF CHRONIC HEPATITIS B: EFFECTIVENESS AND SAFETY IN A SINGLE CENTRE EXPERIENCE
    Hanumantharaya, D. K.
    Khan, R.
    Wilkinson, M.
    Wong, T.
    Tritto, G.
    GUT, 2014, 63 : A244 - A244
  • [30] Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
    Matsubara, Takuya
    Hagiwara, Satoru
    Nishida, Naoshi
    Omaru, Naoya
    Yoshida, Akihiro
    Yamamoto, Tomoki
    Komeda, Yoriaki
    Takenaka, Mamoru
    Kudo, Masatoshi
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345